Early Camizestrant Is Favored Upon ESR1 Mutation Emergence in Breast Cancer

The FDA approved camizestrant for use at the emergence of ESR1 mutations in HR-positive, HER2-negative advanced breast cancer, supported by phase 3 SERENA-6 trial results showing improved progression-free survival and quality of life when switching early to this oral SERD therapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 4 Sep 2026 and 11 Sep 2026.